CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that it has regained full rights to sell its newly approved kidney disease therapy Vafseo (vadadustat) in the U.S. after its partner CSL Vifor ...

Akebia Therapeutics, Inc.AKBA is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently ...

Akebia Therapeutics (NASDAQ:AKBA) shares have traded in a range of $2.5 - $5 since September 2020, and are currently priced at $3.45, giving the biotech a market cap of $552m. Prior to this ...